- Home
- NBXG vs TSHA Comparison
NBXG vs TSHA Comparison
Compare NBXG & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBXG | TSHA |
|---|---|---|
| Founded | N/A | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.5B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NBXG | TSHA |
|---|---|---|
| Price | $13.61 | $4.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $10.56 |
| AVG Volume (30 Days) | 290.6K | ★ 2.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,333,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.94 | $1.13 |
| 52 Week High | $15.66 | $6.02 |
Technical Indicators
Market Signals| Indicator | NBXG | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 48.49 | 44.58 |
| Support Level | $13.53 | $4.41 |
| Resistance Level | $13.94 | $5.39 |
| Average True Range (ATR) | 0.28 | 0.24 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 61.54 | 24.11 |
Price Performance
Historical ComparisonAbout NBXG Neuberger Berman Next Generation Connectivity Fund Inc.
Neuberger Berman Next Generation Connectivity Fund Inc. is a non-diversified, closed-end management investment company. The fund's investment objectives are to provide capital appreciation and income. Under normal market conditions, the Fund will invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. companies, in any market capitalization range, that is relevant to the theme of investing in NextGen Companies.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.